CoChat

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells

Open access
Aparicio, Cristina, Belver, Marina, Enríquez, Lucía, Espeso, Francisco, Núñez, Lucía, Sánchez, Ana, de la Fuente, Miguel Ángel, González-Vallinas, Margarita · 2021 · International Journal of Molecular Sciences
Cited by 86

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is a global public health problem as it is the third most prevalent and the second most lethal cancer worldwide. Major efforts are underway to understand its molecular pathways as well as to define the tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs) or neoantigens, in order to develop an effective treatment. Cell therapies are currently gaining importance, and more specifically chimeric antigen receptor (CAR)-T cell therapy, in which genetically modified T cells are redirected against the tumour antigen of interest. This immunotherapy has emerged as one of the most promising advances in cancer treatment, having successfully demonstrated its efficacy in haematological malignancies. However, in solid tumours, such as colon cancer, it is proving difficult to achieve the same results due to the shortage of TSAs, on-target off-tumour effects, low CAR-T cell infiltration and the immunosuppressive microenvironment. To address these challenges in CRC, new approaches are proposed, including combined therapies, the regional administration of CAR-T cells and more complex CAR structures, among others. This review comprehensively summarises the current landscape of CAR-T cell therapy in CRC from the potential tumour targets to the preclinical studies and clinical trials, as well as the limitations and future perspectives of this novel antitumour strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms222111781

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 95

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  2. Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 · DOI · Paper page
  3. Pareja, 2018, Inmunología del cáncer I: Bases moleculares y celulares de la respuesta inmune antitumoral, Horiz. Médico, 18, 80, 10.24265/horizmed.2018.v18n3.11 · DOI
  4. 2020, A brief history of CAR-T cells: From laboratory to the bedside, Acta Haematol. Pol., 51, 2, 10.2478/ahp-2020-0002 · DOI
  5. Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  6. Bakkach, 2021, Colorectal cancer: From genetic landscape to targeted therapy, J. Oncol., 2021, 9918116
  7. Gallego, 2019, SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018), Clin. Transl. Oncol., 21, 46, 10.1007/s12094-018-02002-w · DOI
  8. Prashanth, 2019, Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors, Prz. Gastroenterol., 14, 89
  9. Meyerhardt, 2005, Drug Therapy: Systemic therapy for colorectal cancer, Arch. Oncol., 352, 476
  10. Wolpin, 2008, Systemic treatment of colorectal cancer, Gastroenterology, 134, 1296, 10.1053/j.gastro.2008.02.098 · DOI · Paper page
  11. Arruebo, 2011, Assessment of the evolution of cancer treatment therapies, Cancers, 3, 3279, 10.3390/cancers3033279 · DOI · Paper page
  12. Carluccio, 2015, Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer, J. Cell. Physiol., 230, 1457, 10.1002/jcp.24886 · DOI
  13. Ishikawa, 2018, Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer, Int. J. Cancer, 142, 2599, 10.1002/ijc.31285 · DOI
  14. Xing, 2019, Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α-gal epitopes, Oncol. Lett., 18, 864
  15. Pan, 2014, The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer, Tumor Biol., 35, 701, 10.1007/s13277-013-1096-1 · DOI
  16. Pan, Q.Z., Zhao, J.J., Yang, C.P., Zhou, Y.Q., Lin, J.Z., Tang, Y., Gu, J.M., Wang, Q.J., Li, Y.Q., and He, J. (2020). Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. Oncoimmunology, 9. · DOI
  17. Zhang, 2014, Effects of cytokine-induced killer cell treatment in colorectal cancer patients: A retrospective study, Biomed. Pharmacother., 68, 715, 10.1016/j.biopha.2014.07.010 · DOI
  18. Zhao, 2016, Autologous Cytokine-Induced Killer Cells improves overall survival of metastatic colorectal cancer patients: Results from a phase II clinical trial, Clin. Colorectal Cancer, 15, 228, 10.1016/j.clcc.2016.02.005 · DOI
  19. Xie, 2017, Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment, World J. Surg. Oncol., 15, 4, 10.1186/s12957-017-1278-1 · DOI
  20. Zhu, 2014, Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy, Biomed Res. Int., 2014, 5, 10.1155/2014/603871 · DOI · Paper page
  21. Gao, 2014, Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients, PLoS ONE, 9, 1
  22. Ishii, 2006, Dendritic cell therapy with interferon-α synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model, Gene Ther., 13, 78, 10.1038/sj.gt.3302608 · DOI
  23. Veluchamy, 2016, Combination of NK cells and cetuximab to enhance anti-tumor responses in RAS mutant metastatic colorectal cancer, PLoS ONE, 11, 1, 10.1371/journal.pone.0157830 · DOI · Paper page
  24. Chen, 2016, Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model, Oncol. Lett., 12, 1868, 10.3892/ol.2016.4835 · DOI
  25. Li, 2018, Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma, Cytotherapy, 20, 134, 10.1016/j.jcyt.2017.09.009 · DOI
  26. Yoshida, 2016, Adoptive chemoimmunotherapy using activated αβ T cells for stage IV colorectal cancer, Anticancer Res., 36, 3741
  27. Parkhust, 2009, Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells, Clin. Cancer Res., 15, 169, 10.1158/1078-0432.CCR-08-1638 · DOI · Paper page
  28. Breman, 2018, Overcoming target driven fratricide for T cell therapy, Front. Immunol., 9, 2940, 10.3389/fimmu.2018.02940 · DOI
  29. Guedan, 2019, Engineering and design of chimeric antigen receptors, Mol. Ther.-Methods Clin. Dev., 12, 145, 10.1016/j.omtm.2018.12.009 · DOI · Paper page
  30. Chmielewski, 2015, TRUCKs: The fourth generation of CARs, Expert Opin. Biol. Ther., 15, 1145, 10.1517/14712598.2015.1046430 · DOI · Paper page
  31. D’Aloia, M.M., Zizzari, I.G., Sacchetti, B., Pierelli, L., and Alimandi, M. (2018). CAR-T cells: The long and winding road to solid tumors. Cell Death Dis., 9. · DOI · Paper page
  32. Trapani, 2017, Immunotherapy of cancer, Aust. Fam. Physician, 46, 194
  33. Wagner, 2018, Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens, World J. Gastroenterol., 24, 5418, 10.3748/wjg.v24.i48.5418 · DOI · Paper page
  34. Feng, 2021, T-cell-based immunotherapy in colorectal cancer, Cancer Lett., 498, 201, 10.1016/j.canlet.2020.10.040 · DOI · Paper page
  35. Bakarurraini, N.A.A.R., Mutalib, N.S.A., Jamal, R., and Abu, N. (2020). The landscape of tumor-specific antigens in colorectal cancer. Vaccines, 8. · DOI
  36. Han, 2020, The old CEACAMs find their new role in tumor immunotherapy, Invest. New Drugs, 38, 1888, 10.1007/s10637-020-00955-w · DOI
  37. Zhang, 2017, Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers, Mol. Ther., 25, 1248, 10.1016/j.ymthe.2017.03.010 · DOI · Paper page
  38. Jelski, 2020, Biochemical markers of colorectal cancer–present and future, Cancer Manag. Res., 12, 4789, 10.2147/CMAR.S253369 · DOI
  39. Lisby, 2021, GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer, Expert Rev. Precis. Med. Drug Dev., 6, 117, 10.1080/23808993.2021.1876518 · DOI
  40. Magee, 2016, GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity, Oncoimmunology, 5, e1227897, 10.1080/2162402X.2016.1227897 · DOI
  41. Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., and Santoni, A. (2018). NKG2D and its ligands: “One for all, all for one”. Front. Immunol., 9. · DOI · Paper page
  42. Dhar, 2018, NKG2D and its ligands in cancer, Curr. Opin. Immunol., 51, 55, 10.1016/j.coi.2018.02.004 · DOI · Paper page
  43. Sabbah, 2020, Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors, Curr. Top. Med. Chem., 20, 815, 10.2174/1568026620666200303123102 · DOI · Paper page
  44. Sigismund, 2018, Emerging functions of the EGFR in cancer, Mol. Oncol., 12, 3, 10.1002/1878-0261.12155 · DOI · Paper page
  45. Huang, 2018, MiR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy, J. Hematol. Oncol., 11, 1
  46. Siena, 2018, Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, Ann. Oncol., 29, 1108, 10.1093/annonc/mdy100 · DOI · Paper page
  47. Styczen, 2015, HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer, Oncotarget, 6, 15065, 10.18632/oncotarget.3527 · DOI · Paper page
  48. Liang, 2018, Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells, Cancer Lett., 433, 165, 10.1016/j.canlet.2018.06.040 · DOI
  49. Eyvazi, 2018, Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, Curr. Cancer Drug Targets, 18, 857, 10.2174/1568009618666180102102311 · DOI
  50. Gires, 2020, Expression and function of epithelial cell adhesion molecule EpCAM: Where are we after 40 years?, Cancer Metastasis Rev., 39, 969, 10.1007/s10555-020-09898-3 · DOI · Paper page
  51. Cho, 2019, The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma, Pathol. Res. Pract., 215, 171, 10.1016/j.prp.2018.10.024 · DOI
  52. Klampatsa, 2021, Mesothelin-targeted CAR-T cell therapy for solid tumors, Expert Opin. Biol. Ther., 21, 473, 10.1080/14712598.2021.1843628 · DOI
  53. Inoue, 2020, Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer, Oncol. Lett., 19, 1741
  54. Nabavinia, 2017, Anti-MUC1 aptamer: A potential opportunity for cancer treatment, Med. Res. Rev., 37, 1518, 10.1002/med.21462 · DOI · Paper page
  55. Li, 2020, PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells, J. Chem. Inf. Model., 25, 1765
  56. Reiswich, V., Gorbokon, N., Luebke, A.M., Burandt, E., Menz, A., Kluth, M., Hube-Magg, C., Wittmer, C., Weidemann, S., and Fraune, C. (2021). Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: A tissue microarray study on 12,381 tumors. J. Pathol. Clin. Res. · DOI
  57. Akbari, 2020, CD133: An emerging prognostic factor and therapeutic target in colorectal cancer, Cell Biol. Int., 44, 368, 10.1002/cbin.11243 · DOI · Paper page
  58. Abbasian, 2019, The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis, J. Cell. Physiol., 234, 8192, 10.1002/jcp.27619 · DOI · Paper page
  59. Lee, 2018, c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival, Clin. Colorectal Cancer, 17, 165, 10.1016/j.clcc.2018.02.013 · DOI
  60. Safaie Qamsari, E., Safaei Ghaderi, S., Zarei, B., Dorostkar, R., Bagheri, S., Jadidi-Niaragh, F., Somi, M.H., and Yousefi, M. (2017). The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumour Biol., 39. · DOI
  61. Rahbar, 2018, PSMA Theranostics: Current Status and Future Directions, Mol. Imaging, 17, 1, 10.1177/1536012118776068 · DOI · Paper page
  62. Cuda, 2020, PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer, J. Nucl. Med., 61, 1576, 10.2967/jnumed.119.233312 · DOI
  63. Ang, 2017, Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis, Oncotarget, 8, 13545, 10.18632/oncotarget.14592 · DOI · Paper page
  64. Chi, 2019, Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12, Cancer Med., 8, 4753, 10.1002/cam4.2361 · DOI · Paper page
  65. Deng, 2019, Antitumor activity of NKG2D CAR-T cell against human colorectal cancer cells in vitro and in vivo, Am. J. Cancer Res., 9, 945
  66. Ramos, 2018, In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas, Mol. Ther., 26, 2727, 10.1016/j.ymthe.2018.09.009 · DOI · Paper page
  67. Hombach, 2019, Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors, Mol. Ther., 27, 1825, 10.1016/j.ymthe.2019.06.007 · DOI · Paper page
  68. Teng, 2019, Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model, J. Immunother., 42, 33, 10.1097/CJI.0000000000000251 · DOI · Paper page
  69. Hombach, A.A., Geumann, U., Günther, C., Hermann, F.G., and Abken, H. (2020). IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells. Cells, 9. · DOI · Paper page
  70. Sureban, S.M., Berahovich, R., Zhou, H., Xu, S., Wu, L., Ding, K., May, R., Qu, D., Bannerman-menson, E., and Golubovskaya, V. (2020). DCLK1 Monoclonal Antibody-Based CAR-T Cells Asa Novel Treatment Strategy against Human Colorectal Cancers. Cancers, 12. · DOI
  71. Katz, 2016, Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery, Cancer Gene Ther., 23, 142, 10.1038/cgt.2016.14 · DOI · Paper page
  72. Zhang, 2021, The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice, Mol. Ther. Oncolytics, 20, 556, 10.1016/j.omto.2021.02.013 · DOI
  73. Mullins, 2020, Mouse models of colorectal cancer: Past, present and future perspectives, World J. Gastroenterol., 26, 1394, 10.3748/wjg.v26.i13.1394 · DOI · Paper page
  74. Feng, 2017, Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma, J. Hematol. Oncol., 10, 1, 10.1186/s13045-016-0378-7 · DOI · Paper page
  75. Zhou, 2019, Construction of chimeric antigen receptor-modified T cells targeting EpCAM and assessment of their anti-tumor effect on cancer cells, Mol. Med. Rep., 20, 2355
  76. Ang, 2020, Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts, Mol. Ther. Oncolytics, 17, 421, 10.1016/j.omto.2020.04.013 · DOI
  77. Goff, 2019, Pilot trial of adoptive transfer of chimeric antigen receptor-Transduced T cells targeting EGFRvIII in patients with glioblastoma, J. Immunother., 42, 126, 10.1097/CJI.0000000000000260 · DOI · Paper page
  78. Sampson, 2014, EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss, Clin. Cancer Res., 20, 972, 10.1158/1078-0432.CCR-13-0709 · DOI · Paper page
  79. Katz, 2020, HITM-SIR: Phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases, Cancer Gene Ther., 27, 341, 10.1038/s41417-019-0104-z · DOI
  80. Katz, 2020, HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery, J. Immunother. Cancer, 8, 1, 10.1136/jitc-2020-001097 · DOI
  81. Lichtenstern, C.R., Ngu, R.K., Shalapour, S., and Karin, M. (2020). Immunotherapy, Inflammation and Colorectal Cancer. Cells, 9. · DOI · Paper page
  82. Morgan, 2020, Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells, Front. Immunol., 11, 1965, 10.3389/fimmu.2020.01965 · DOI
  83. Sallman, 2018, Abstract CT129: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia, Cancer Res., 78, CT129, 10.1158/1538-7445.AM2018-CT129 · doi:10.1158/1538-7445.am2018-ct129
  84. Depil, 2020, ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges, Nat. Rev. Drug Discov., 19, 185, 10.1038/s41573-019-0051-2 · DOI · Paper page
  85. Yazdanifar, M., Barbarito, G., Bertaina, A., and Airoldi, I. (2020). γδ T Cells: The Ideal Tool for Cancer Immunotherapy. Cells, 9. · DOI
  86. Prenen, 2021, Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC, J. Clin. Oncol., 39, 74, 10.1200/JCO.2021.39.3_suppl.74 · doi:10.1200/jco.2021.39.3_suppl.74
  87. Dai, 2020, Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: A single-arm, open-label, phase II trial, Oncoimmunology, 9, 1, 10.1080/2162402X.2020.1846926 · DOI · Paper page
  88. Lonez, 2018, Van Den Canon, J.-L.; Carrasco, J.; Verma, B.; et al. Abstract CT123: A phase I study assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases, Cancer Res., 78, CT123, 10.1158/1538-7445.AM2018-CT123 · doi:10.1158/1538-7445.am2018-ct123
  89. Braun, 2018, Abstract CT134: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of a NKG2D-based CAR-T therapy CYAD-01, in patients with unresectable liver metastases from colorectal cancer, Cancer Res., 78, CT134, 10.1158/1538-7445.AM2018-CT134 · doi:10.1158/1538-7445.am2018-ct134
  90. Sur, D., Havasi, A., Cainap, C., Samasca, G., Burz, C., Balacescu, O., Lupan, I., Deleanu, D., and Irimie, A. (2020). Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J. Clin. Med., 9. · DOI
  91. Zhang, 2019, Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies, Cancer Lett., 458, 123, 10.1016/j.canlet.2019.05.017 · DOI
  92. Bollard, 2002, Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity, Blood, 99, 3179, 10.1182/blood.V99.9.3179 · DOI · Paper page
  93. Kono, 1996, Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity, Eur. J. Immunol., 26, 1308, 10.1002/eji.1830260620 · DOI · Paper page
  94. Leen, 2014, Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor, Mol. Ther., 22, 1211, 10.1038/mt.2014.47 · DOI · Paper page
  95. Dillard, 2020, Colorectal cysts as a validating tool for CAR therapy, BMC Biotechnol., 20, 1, 10.1186/s12896-020-00623-0 · DOI

Cited by

See all 86

Metadata

Authors
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-10-29
Volume
22
Issue
21
Pages
11781
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3209309812
Cited by
86
References
11
FWCI
4.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. https://app.cochat.ai/papers/10.3390/ijms222111781
The paper
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M. (2021). Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222111781

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.